PBYI

Puma Biotechnology's stock has experienced fluctuations due to recent financial announcements and clinical trial updates. The stock has increased by 36.21% over the last six months and 135.71% over the last year. In Q4 2025, the company reported total revenue of $75.5 million and a net income of $13.4 million, but the stock plunged due to weaker-than-expected revenue guidance. In Q1 2026, Puma reported a net loss of $3.8 million with total revenue of $44.8 million, attributed to inventory drawdown. The company raised its full-year 2026 net NERLYNX product revenue guidance to $202 million to $206 million and net income guidance to $16 million to $19 million. Puma Biotechnology is now debt-free. Interim Phase II clinical data on alisertib demonstrated enhanced efficacy in biomarker-defined patient groups.